Lowest Price Guaranteed From USD 4,799
Published
July 2023
Pages
716
View Count
66014
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
We are aware that various second and third generation ADCs that are being developed by different companies, have shown significant improvements, in terms of clinical results, compared to traditional ADCs. As a result, novel ADC technologies have garnered the attention of physicians, patients and their families, having demonstrated improved clinical outcomes. We are optimistic about the growth of the ADCs market and believe that competition in this domain is likely to increase in the future.
- Executive Director / Chief Innovation Officer, a big pharma company
The global antibody drug conjugate market is estimated to be worth USD 7.72 billion in 2023 and expected to grow at compounded annual growth rate (CAGR) of 9.63% during the forecast period. Antibody drug conjugates are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies.
14 antibody-drug conjugates, till date, have been approved by the USFDA for therapeutic use; these are ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), polatuzumab vedotin-piiq (Polivy), enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu), belantamab mafodotin-blmf (Blenrep), mirvetuximab soravtansine (Elahere), tisotumab vedotin (Tivdak), cetuximab sarotalocan (Akalux), disitamab vedotin (Aidixi) and loncastuximab tesirine-lpyl (Zynlonta).
The success of ADC therapeutics can be attributed to their high tumor selectivity and cell-killing potential of these antibodies, while limiting off target toxicities. Ongoing research in this direction is driven by encouraging results achieved in past clinical trials, which were mostly focused on various solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the antibody drug conjugate market is likely to witness significant growth during the forecast period.
The Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size and future opportunities for the antibody drug conjugate companies either developing the drugs or providing the necessary ADC technology, during the forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibody drug conjugate market are briefly discussed below.
Antibody drug conjugates landscape features the presence of over 140 very large, large, mid-sized and small drug developers. It is worth mentioning that, currently, more than 280 antibody drug conjugates are either approved or being evaluated in clinical trials, whereas 250 candidates are in preclinical stages of development. All the approved ADC therapeutics have been developed to target either solid tumor or hematological cancer. Majority of the pipeline antibody-drug conjugates are being developed for the treatment of cancer, particularly breast cancer.
ADC therapeutics offer a promising approach by targeting multiple disease pathways simultaneously. Kadcyla was the first HER2 ADC to be approved by FDA for the treatment of patients with breast cancer. Since then, two more ADC therapeutics, Daiichi Sankyo - AstraZeneca’s Enhertu and Immunomedics’ Trodelvy have received approval for the treatment of metastatic breast cancer as second-line treatment. Further, Daiichi Sankyo - AstraZeneca’s Enhertu is expected to get EU approval for the treatment of non-small cell lung cancer in 2023. Presently, there are over 30 antibody drug conjugates that are under development for the treatment of breast cancer. According to the WHO statistics, breast cancer is the most prevalent cancer worldwide with an estimated 7.8 million women living with breast cancer at the end of 2020. In the same year, 2.3 million new cases of women diagnosed with breast cancer were reported.
In addition to breast cancer, the approved ADCs target indications, such as leukemia, lymphoma, urothelial cancer, multiple myeloma, cervical cancer, and ovarian cancer. The increasing prevalence of oncological disorders and a rich pipeline of ADC therapeutics targeting cancer is expected to drive the antibody drug conjugate market during the forecast period.
The global antibody drug conjugate market is estimated to be worth USD 7.72 billion in 2023. These represent the revenues generated by the sales of various ADC therapeutics. Driven by the growing demand for effective therapeutics for treatment of oncological disorders, along with growing developmental pipeline and encouraging clinical trial results, the antibody drug conjugates market is anticipated to grow at a CAGR of 9.63% during the forecast period.
Antibody drug conjugates have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional cancer treatment options) of antibody-drug conjugates. Therefore, the increasing prevalence of various oncological disorders is one of the key drivers for the antibody drug conjugate market.
Currently, more than 70 antibody drug conjugates are either approved or being evaluated in clinical trials targeting HER2 for the treatment of various oncological disorders, particularly breast cancer. Roche’s Kadcyla was the first HER2 ADC to receive FDA approval in 2013, followed by Daiichi Sankyo / AstraZeneca’s Enhertu in 2019. Another HER2 ADC, Aidixi, received conditional marketing approval from China’s National Medical Products Administration for treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy. The drug has been developed by China based RemeGen Biosciences. Seagen acquired exclusive worldwide license, outside of Greater China, for development and commercialization of Aidixi from RemeGen. The antibody drug conjugate market for HER2 ADC is anticipated to grow at a CAGR of 8.16% during the forecast period.
In the past few years, several well-funded start-ups / small companies, offering antibody drug conjugate having advanced linkers and more potent warheads have been established. Of these, majority of the companies are based in North America. Additionally, FDA has been actively reviewing and approving ADC therapeutics for cancer. The rising incidence of cancer in the US will drive the adoption of antibody drug conjugates. As per the American Cancer Society, over 1.9 million cancer patients were estimated to be diagnosed in the US in 2022.
The major risk factors for cancer include tobacco use, excess body weight, excess alcohol consumption, and infectious agents. All these factors will drive the market growth of the North American antibody drug conjugate market during the forecast period. In order to increase the adoption of antibody-drug conjugates among target population, ADC developers are offering several patient assistance / support programs which help the patient to deal with medical expenses. Examples of such programs include Ambrx patient assistance program, Bayer oncology patient assistance program and Genentech patient assistance program.
Antibody drug conjugates are a type of targeted cancer therapy that uses monoclonal antibodies to deliver a toxic payload to cancer cells. The most common cytotoxic payloads used in antibody drug conjugates are MMAE and DM4. The majority of ADCs use valine citrulline (VC) linkers or peptide linkers to attach the antibody to the toxic payload.
The development of novel ADC technologies, such as site-specific conjugation and novel linker technologies are expected to drive the antibody drug conjugate market growth in the coming years.
Over the years, companies involved in the development of antibody drug conjugates (ADCs) have made significant efforts to evaluate the efficacy of antibody drug conjugates in clinical studies, for the treatment of various cancers. Currently, 150 antibody drug conjugates are being evaluated in more than 550 trials across different geographical regions. Majority of these trials (385) were registered in North America. Within this region, the maximum number of trials were / are being conducted in the US (379). Additionally, till February 2023, majority of the patients (39,226) were enrolled in trials conducted in North America, accounting for about 45% of the overall enrollment.
Currently, several partnerships have been inked by various industry and non-industry players engaged in the development of antibody-drug conjugates. It is worth highlighting that over 50 partnerships were inked in 2022 alone. Majority of such deals are focused on product and technology licensing. Further, in one of the largest acquisitions in the biopharmaceutical industry, Pfizer acquired Seagen in March 2023 for a total enterprise value of approximately USD 43 billion, with an aim to accelerate cancer breakthroughs in this market. This deal intends to bring new solutions to patients by combining Seagen’s ADC technology with Pfizer’s global reach. In addition to this, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to progress their R&D efforts related to the development of novel ADC therapeutics.
Examples of the key antibody drug conjugate companies (the complete list of players is available in the full report) include ADC Therapeutics, Astellas Pharma, AstraZeneca, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, Pfizer, RemeGen. This market report includes an easily searchable excel database of all the antibody drug conjugate companies worldwide.
Several recent developments have taken place in the field of antibody drug conjugate. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Base Year |
2022 |
|
|
Forecast Period |
2023 – 2035 |
|
|
Market Size 2023 |
$7.72 billion |
|
|
CAGR |
9.63% |
|
|
Target Disease Indication |
|
|
|
Therapeutic Area |
|
|
|
Linker |
|
|
|
Payload |
|
|
|
Target Antigens |
|
|
|
Key Geographical Regions |
|
|
|
Key Companies Profiled |
|
|
|
Customization Scope |
15% Free Customization Option |
|
|
Excel Data Packs (Complimentary) |
|
|
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:
One of the key objectives of this market report was to estimate the current market size and the future growth potential of antibody drug conjugates over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the ADC market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as target disease indication (breast cancer, B-cell lymphoma, lung cancer, multiple myeloma, acute lymphoblastic leukemia, gastric cancer, renal cancer, cervical cancer and other target disease indications), therapeutic area (hematological cancer and solid tumors), linker (valine-citrulline, succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, tetrapeptide-based linker, maleimide, maleimidocaproyl, valine-alanine, hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) and other linkers), payload (monomethyl auristatin E, DM1, duocarmycin, SN-38 / irinotecan, monomethyl auristatin F, SG3199, ozogamicin, DM4 and other payloads), target antigens (HER-2 (ERBB2), CD79b, TROP-2, BCMA (TNFRSF17 / BCM), CD19, CD22, tissue factor, CD30, CEACAM5, nectin 4 and others) and key geographical regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Antibody Drug Conjugate Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Antibody Drug Conjugates
3.3.1. History of Antibody Drug Conjugates
3.3.2. Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
3.3.3. Components of Antibody Drug Conjugates
3.3.3.1. Antibody
3.3.3.2. Cytotoxin
3.3.3.3. Linker
3.3.4. Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
3.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
3.3.5.1. Absorption
3.3.5.2. Distribution
3.3.5.3. Metabolism and Elimination
3.4. Concluding Remarks
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Therapies Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Line of Treatment
4.2.5. Analysis by Dosing Frequency
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Target Antigen
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Payload / Cytotoxin / Warhead
4.2.10. Analysis by Type of Payload
4.2.11. Analysis by Linker
4.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
4.3. Antibody Drug Conjugate: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Therapies
5. TARGET COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters
5.3. Methodology
5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
5.4.1. Three-Dimensional Bubble Analysis
5.4.1.1. Targets of Approved / Marketed Drugs
5.4.1.2. Targets of Phase III Drugs
5.4.1.3. Targets of Phase II Drugs
5.4.1.4. Targets of Phase I Drugs
5.4.1.5. Targets of Pre-Clinical Drugs
5.4.2. Six-Dimensional Spider Web Analysis
6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. ADC Therapeutics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Zynlonta
6.2.4. Recent Developments and Future Outlook
6.3. Astellas Pharma
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. Padcev
6.3.4. Recent Developments and Future Outlook
6.4. AstraZeneca
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. Enhertu
6.4.4. Recent Developments and Future Outlook
6.5. Byondis
6.5.1. Company Overview
6.5.2. Financial Information
6.5.2.1. Pipeline Overview
6.5.3. Trastuzumab duocarmazine
6.5.4. Recent Developments and Future Outlook
6.6. Daiichi Sankyo
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. Enhertu
6.6.4. Recent Developments and Future Outlook
6.7. Genentech (Subsidiary of Roche)
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. Kadcyla
6.7.3.2. Polivy
6.7.4. Recent Developments and Future Outlook
6.8. Gilead Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. Trodelvy
6.8.4. Recent Developments and Future Outlook
6.9. ImmunoGen
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Pipeline Overview
6.9.3.1. Elahere
6.9.4. Recent Developments and Future Outlook
6.10. Pfizer
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Overview
6.10.3.1. Mylotarg
6.10.3.2. Besponsa
6.10.4. Recent Developments and Future Outlook
6.11. RemeGen
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Overview
6.11.3.1. Disitamab vedotin
6.11.4. Recent Developments and Future Outlook
6.12. Seagen
6.12.1. Company Overview
6.12.2. Financial Information
6.12.3. Pipeline Overview
6.12.3.1. Adcetris
6.12.3.2. Padcev
6.12.3.3. Tivdak
6.12.4. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antibody Drug Conjugates: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Status and Patients Enrolled
7.3.4. Analysis by Trial Registration Year and Trial Status
7.3.5. Analysis by Trial Registration Year and Patients Enrolled
7.3.6. Analysis by Trial Phase
7.3.7. Analysis by Trial Phase and Patients Enrolled
7.3.8. Analysis by Type of Sponsor / Collaborator
7.3.9. Analysis by Target Population
7.3.10. Analysis by Study Design
7.3.11. Most Active Industry Players: Analysis by Number of Trials
7.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
7.3.13. Analysis of Clinical Trials by Geography
7.3.14. Analysis of Patients Enrolled by Geography
8. KEY OPINION LEADERS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Antibody Drug Conjugates: Key Opinion Leaders
8.4.1. Analysis by Type of KOLs
8.4.2. Analysis by Qualification
8.4.3. Analysis by Affiliated Organization
8.4.4. Analysis by Type of Organization
8.4.5. Analysis by Geographical Location of KOLs
8.4.6. Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
8.4.7. Most Prominent KOLs: Analysis by RA score
8.4.8. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9. COMBINATION THERAPIES
9.1. Chapter Overview
9.2. Combination Therapies: History of Development
9.3. Combination Therapies: FDA Guidelines
9.3.1. Combination of Marketed Drugs
9.3.2. Combinations of Marketed Drugs with New Molecular Entities
9.3.3. Combination of New Molecular Entities
9.4. Combination Therapies: Antibody Drug Conjugates
9.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
9.4.1.1. Analysis by Type of Therapy
9.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
9.4.2.1. Analysis by Phase of Development
9.4.2.2. Analysis by Trial Status
9.4.2.3. Analysis by Target Disease Indication
9.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
9.4.2.5. Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials
9.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Purpose of Partnership
10.3.5. Analysis by Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Analysis by Geography
10.3.7.1. International and Local Agreements
10.3.7.2. Intercontinental and Intracontinental Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis
11.3.1. Analysis by Year of Funding
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Year and Type of Funding
11.3.5. Analysis by Type of Investor
11.3.6. Analysis by Amount Invested by Geography
11.3.6.1. Analysis by Region
11.3.6.2. Analysis by Country
11.3.7. Most Active Players: Analysis by Number of Funding Instances
11.3.8. Most Active Players: Analysis by Amount Invested
11.3.9. Key Investors: Analysis by Number of Funding Instances
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Patent Application Year
12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Individual Assignees: Analysis by Number of Patents
12.4. Antibody Drug Conjugate: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics
12.5. Antibody Drug Conjugate: Patent Valuation
12.6. Leading Patents by Number of Citations
13. ACADEMIC GRANTS ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Grants Analysis
13.3.1. Analysis by Year of Grant Award
13.3.2. Analysis by Amount Awarded
13.3.3. Analysis by Funding Institute
13.3.4. Analysis by Support Period
13.3.5. Analysis by Type of Grant Application
13.3.6. Analysis by Purpose of Grant Award
13.3.7. Analysis by Activity Code
13.3.8. Analysis by Study Section Involved
13.3.9. Popular NIH Departments: Analysis by Number of Grants
13.3.9.1. Prominent Program Officers: Analysis by Number of Grants
13.3.9.2. Popular Recipient Organizations: Analysis by Number of Grants
13.3.9.3. Popular Recipient Organizations: Analysis by Grant Amount
13.3.10. Analysis by Region of Recipient Organization
14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
14.5.1. Participation in the Global Events
14.5.2. Collaboration with External Stakeholders and Pharmaceuticals Firms
14.5.3. Geographical Expansion
14.5.4. Awareness Through Product Website
14.6. Concluding Remarks
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Adcetris: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professional
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.2.4. Patient Support Services
15.6. Besponsa: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professional
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.2.4. Patient Support Services
15.7. Enhertu: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professional
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.2.4. Patient Support Services
15.8. Kadcyla: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professional
15.8.2.2. Message for patients
15.8.2.3. Informative Downloads
15.8.2.4. Patient Support Services
15.9. Mylotarg: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professional
15.9.2.2. Message for patients
15.9.2.3. Informative Downloads
15.9.2.4. Patient Support Services
15.10. Polivy: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professional
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.2.4. Patient Support Services
15.11. Trodelvy: Promotional Analysis
15.11.1. Drug Overview
15.11.2. Product Website Analysis
15.11.2.1. Message for Healthcare Professional
15.11.2.2. Message for Patients
15.11.2.3. Informative Downloads
15.11.2.4. Patient Support Services
16. SUCCESS PROTOCOL ANALYSIS
16.1. Chapter Overview
16.2. Antibody Drug Conjugates: Success Protocol Analysis
16.3. Adcetris (Seagen / Takeda Oncology)
16.3.1. Overview
16.3.2. Approval Timeline
16.3.3. Success Protocol Analysis
16.4. Aidixi (RemeGen)
16.4.1. Overview
16.4.2. Approval Timeline
16.4.3. Success Protocol Analysis
16.5. Akalux (Rakuten Medical)
16.5.1. Overview
16.5.2. Approval Timeline
16.5.3. Success Protocol Analysis
16.6. Besponsa (Pfizer / UCB)
16.6.1. Overview
16.6.2. Approval Timeline
16.6.3. Success Protocol Analysis
16.7. Blenrep (GlaxoSmithKline)
16.7.1. Overview
16.7.2. Approval Timeline
16.7.3. Success Protocol Analysis
16.8. Elahere (ImmunoGen)
16.8.1. Overview
16.8.2. Approval Timeline
16.8.3. Success Protocol Analysis
16.9. Enhertu (Daiichi Sankyo / AstraZeneca)
16.9.1. Overview
16.9.2. Approval Timeline
16.9.3. Success Protocol Analysis
16.10. Kadcyla (Genentech / ImmunoGen)
16.10.1. Overview
16.10.2. Approval Timeline
16.10.3. Success Protocol Analysis
16.11. Padcev (Seagen / Astellas Pharma)
16.11.1. Overview
16.11.2. Approval Timeline
16.11.3. Success Protocol Analysis
16.12. Polivy (Genentech)
16.12.1. Overview
16.12.2. Approval Timeline
16.12.3. Success Protocol Analysis
16.13. Tivdak (Seagen / Genmab)
16.13.1. Overview
16.13.2. Approval Timeline
16.13.3. Success Protocol Analysis
16.14. Trodelvy (Gilead Sciences)
16.14.1. Overview
16.14.2. Approval Timeline
16.14.3. Success Protocol Analysis
16.15. Zynlonta (ADC Therapeutics)
16.15.1. Overview
16.15.2. Approval Timeline
16.15.3. Success Protocol Analysis
16.16. Concluding Remarks
17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. Antibody Drug Conjugates: Conjugation Technologies
17.2.1. Chemical Conjugation
17.2.2. Enzymatic Conjugation
17.3. Antibody Drug Conjugates: List of Conjugation Technologies
17.4. Antibody Drug Conjugates: Linker Technologies
17.4.1. Non-cleavable Linkers
17.4.2. Cleavable Linker
17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
17.6. Concluding Remarks
18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. Antibody Drug Conjugates: Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates
19.3. Antibody Drug Conjugates Market: Cost Price Analysis
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody-Drug Conjugates
20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES
20.1. Chapter Overview
20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
20.9. CMOs with Linker Manufacturing Capabilities
20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.11. CMOs with Conjugation Capabilities
20.12. Antibody Drug Conjugate One-Stop-Shops
20.13. Increasing Demand for One-Stop-Shops
21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics
21.2. Companion Diagnostics for Antibody Drug Conjugates
21.3. Companion Diagnostics For Antibody Therapeutics
21.3.1. Analysis by Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Prominent Players: Analysis by Number of Tests
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.2.1. Improved Safety and Patient Adherence
22.2.2. Rise of Next-Generation Conjugation Technologies
22.2.3. Robust Pipeline with Multiple Late Stage Product Candidates
22.2.4. Growing Involvement of Academic Institutes
22.3. Weaknesses
22.3.1. Technical Complexities Associated with Product Development
22.3.2. Manufacturing, Logistics and Supply Chain Challenges
22.3.3. Batch to Batch Inconsistencies
22.4. Opportunities
22.4.1. Increasing Collaborations and VC Funding
22.4.2. Widening Therapeutics Reach
22.4.3. Life Cycle Management
22.4.4. Combination Therapies
22.4.5. Opportunities for CMOs
22.5. Threats
22.5.1. Failure of Clinical / Marketed Candidates
22.5.2. Increased Competition from Other Therapeutic Classes
23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Forecast Methodology and Key Assumptions
23.3. Global Antibody Drug Conjugates Market, 2023-2035
23.3.1. Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
23.3.1.1. Antibody Drug Conjugates Market for Breast Cancer, 2023-2035
23.3.1.2. Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035
23.3.1.3. Antibody Drug Conjugates Market for Lung Cancer, 2023-2035
23.3.1.4. Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035
23.3.1.5. Antibody Drug Conjugates Market for Renal Cancer, 2023-2035
23.3.1.6. Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035
23.3.1.7. Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035
23.3.1.8. Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035
23.3.1.9. Antibody Drug Conjugates Market for Other Disease Indications, 2023-2035
23.3.2. Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035
23.3.2.1. Antibody Drug Conjugates Market for Solid Tumors, 2023-2035
23.3.2.2. Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035
23.3.3. Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035
23.3.3.1. Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035
23.3.3.2. Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, 2023-2035
23.3.3.3. Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035
23.3.3.4. Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035
23.3.3.5. Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035
23.3.3.6. Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035
23.3.3.7. Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035
23.3.3.8. Antibody Drug Conjugates Market for Other Linkers, 2023-2035
23.3.4. Antibody Drug Conjugates Market: Distribution by Type of Payload, 2023 and 2035
23.3.4.1. Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, 2023-2035
23.3.4.2. Antibody Drug Conjugates Market for DM1 Payloads, 2023-2035
23.3.4.3. Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, 2023-2035
23.3.4.4. Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, 2023-2035
23.3.4.5. Antibody Drug Conjugates Market for Duocarmycin Payloads, 2023-2035
23.3.4.6. Antibody Drug Conjugates Market for SG3199 Payloads, 2023-2035
23.3.4.7. Antibody Drug Conjugates Market for Ozogamicin Payloads, 2023-2035
23.3.4.8. Antibody Drug Conjugates Market for DM4 Payloads, 2023-2035
23.3.4.9. Antibody Drug Conjugates Market for Other Payloads, 2023-2035
23.3.5. Global Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035
23.3.5.1. Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035
23.3.5.2. Antibody Drug Conjugates Market for CD79b, 2023-2035
23.3.5.3. Antibody Drug Conjugates Market for TROP-2, 2023-2035
23.3.5.4. Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035
23.3.5.5. Antibody Drug Conjugates Market for CD19, 2023-2035
23.3.5.6. Antibody Drug Conjugates Market for Nectin 4, 2023-2035
23.3.5.7. Antibody Drug Conjugates Market for Tissue Factor, 2023-2035
23.3.5.8. Antibody Drug Conjugates Market for CD22, 2023-2035
23.3.5.9. Antibody Drug Conjugates Market for CD30, 2023-2035
23.3.5.10. Antibody Drug Conjugates Market for CEACAM5, 2023-2035
23.3.5.11. Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035
23.3.6. Antibody Drug Conjugates Market: Distribution by Geographical Regions, 2023 and 2035
23.3.6.1. Antibody Drug Conjugates Market in North America, 2023-2035
23.3.6.1.1. Antibody Drug Conjugates Market in US, 2023-2035
23.3.6.1.2. Antibody Drug Conjugates Market in Canada, 2023-2035
23.3.6.2. Antibody Drug Conjugates Market in Europe, 2023-2035
23.3.6.2.1. Antibody Drug Conjugates Market in Germany, 2023-2035
23.3.6.2.2. Antibody Drug Conjugates Market in UK, 2023-2035
23.3.6.2.3. Antibody Drug Conjugates Market in France, 2023-2035
23.3.6.2.4. Antibody Drug Conjugates Market in Italy, 2023-2035
23.3.6.2.5. Antibody Drug Conjugates Market in Spain, 2023-2035
23.3.6.3. Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035
23.3.6.3.1. Antibody Drug Conjugates Market in China, 2023-2035
23.3.6.3.2. Antibody Drug Conjugates Market in Australia, 2023-2035
23.3.6.3.3. Antibody Drug Conjugates Market in Japan, 2023-2035
23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
23.4.1. Adcetris
23.4.1.1. Sales Forecast (USD Billion)
23.4.1.2. Net Present Value (USD Billion)
23.4.1.3. Value Creation Analysis
23.4.2. Aidixi
23.4.2.1. Sales Forecast (USD Billion)
23.4.2.2. Net Present Value (USD Billion)
23.4.2.3. Value Creation Analysis
23.4.3. Besponsa
23.4.3.1. Sales Forecast (USD Billion)
23.4.3.2. Net Present Value (USD Billion)
23.4.3.3. Value Creation Analysis
23.4.4. Blenrep
23.4.4.1. Sales Forecast (USD Billion)
23.4.4.2. Net Present Value (USD Billion)
23.4.4.3. Value Creation Analysis
23.4.5. Elahere
23.4.5.1. Sales Forecast (USD Billion)
23.4.5.2. Net Present Value (USD Billion)
23.4.5.3. Value Creation Analysis
23.4.6. Enhertu
23.4.6.1. Sales Forecast (USD Billion)
23.4.6.2. Net Present Value (USD Billion)
23.4.6.3. Value Creation Analysis
23.4.7. Kadcyla
23.4.7.1. Sales Forecast (USD Billion)
23.4.7.2. Net Present Value (USD Billion)
23.4.7.3. Value Creation Analysis
23.4.8. Padcev
23.4.8.1. Sales Forecast (USD Billion)
23.4.8.2. Net Present Value (USD Billion)
23.4.8.3. Value Creation Analysis
23.4.9. Polivy
23.4.9.1. Sales Forecast (USD Billion)
23.4.9.2. Net Present Value (USD Billion)
23.4.9.3. Value Creation Analysis
23.4.10. Tivdak
23.4.10.1. Sales Forecast (USD Billion)
23.4.10.2. Net Present Value (USD Billion)
23.4.10.3. Value Creation Analysis
23.4.11. Trodelvy
23.4.11.1. Sales Forecast (USD Billion)
23.4.11.2. Net Present Value (USD Billion)
23.4.11.3. Value Creation Analysis
23.4.12. Zynlonta
23.4.12.1. Sales Forecast (USD Billion)
23.4.12.2. Net Present Value (USD Billion)
23.4.12.3. Value Creation Analysis
23.4.13. Datopotamab Deruxtecan
23.4.13.1. Sales Forecast (USD Billion)
23.4.13.2. Net Present Value (USD Billion)
23.4.13.3. Value Creation Analysis
23.4.14. Patritumab Deruxtecan
23.4.14.1. Sales Forecast (USD Billion)
23.4.14.2. Net Present Value (USD Billion)
23.4.14.3. Value Creation Analysis
23.4.15. SHR-A1811
23.4.15.1. Sales Forecast (USD Billion)
23.4.15.2. Net Present Value (USD Billion)
23.4.15.3. Value Creation Analysis
23.4.16. SKB264
23.4.16.1. Sales Forecast (USD Billion)
23.4.16.2. Net Present Value (USD Billion)
23.4.16.3. Value Creation Analysis
23.4.17. TAA013
23.4.17.1. Sales Forecast (USD Billion)
23.4.17.2. Net Present Value (USD Billion)
23.4.17.3. Value Creation Analysis
23.4.18. Telisotuzumab Vedotin
23.4.18.1. Sales Forecast (USD Billion)
23.4.18.2. Net Present Value (USD Billion)
23.4.18.3. Value Creation Analysis
23.4.19. Trastuzumab Duocarmazine
23.4.19.1. Sales Forecast (USD Billion)
23.4.19.2. Net Present Value (USD Billion)
23.4.19.3. Value Creation Analysis
23.4.20. Tusamitamab Ravtansine
23.4.20.1. Sales Forecast (USD Billion)
23.4.20.2. Net Present Value (USD Billion)
23.4.20.3. Value Creation Analysis
23.4.21. Upifitamab Rilsodotin
23.4.21.1. Sales Forecast (USD Billion)
23.4.21.2. Net Present Value (USD Billion)
23.4.21.3. Value Creation Analysis
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer
24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.6. PolyTherics (an Abzena company)
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Former Chief Executive Officer
24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
24.8. CytomX Therapeutics
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Former Chief Business Officer
24.10. Cerbios-Pharma
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
24.11. Eisai
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Toshimitsu Uenaka, President and Takashi Owa, Senior Vice President and Chief Scientific Officer
24.12. AbTis
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Justin Oh, Chief Business Officer
24.13. AmbrX
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Sukumar Sakamuri, Former Vice President and Head of Chemistry
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Vice President, Business Development
24.15. Pierre Fabre
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Christian Bailly, Former Director
24.16. Catalent Pharma Solutions
24.16.1. Company Snapshot
24.16.2. Interview Transcript: Jennifer L. Mitcham, Former Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Former Group Product Manager
24.17. Lonza
24.17.1. Company Snapshot
24.17.2. Interview Transcript: Laurent Ducry, Former Head of Bioconjugates Commercial Development
24.18. Piramal Healthcare
24.18.1. Company Snapshot
24.18.2. Interview Transcript: Mark Wright, Former Site Head
24.19. Ajinomoto Bio-Pharma Services
24.19.1. Company Snapshot
24.19.2. Interview Transcript: Tatsuya Okuzumi, General Manager, Business Development, CDMO Business
24.20. Cardiff University
24.20.1. Company Snapshot
24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
24.21. Anonymous, Director, Business Development, Leading CMO
24.22. Anonymous, Chief Executive Officer, Leading CMO
25. CONCLUSION
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Overview
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Academic Grants Analysis
Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Antibody Drug Conjugates: Development History
Figure 3.3 Comparative Analysis of Pharmacokinetic Properties of Antibody Drug Conjugates: Dosage Regimen, Cmax and T1/2
Figure 3.4 Components of Antibody Drug Conjugates
Figure 4.1 Antibody Drug Conjugates: Distribution by Status of Development
Figure 4.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 4.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
Figure 4.4 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 4.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 4.6 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 4.7 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 4.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 4.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 4.10 Antibody Drug Conjugates: Distribution by Type of Payload
Figure 4.11 Antibody Drug Conjugates: Distribution by Linker
Figure 4.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 4.13 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 4.14 Antibody Drug Conjugate Developers: Distribution by Company Size
Figure 4.15 Antibody Drug Conjugate Developers: Distribution by Location of Headquarters
Figure 4.16 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
Figure 4.17 Most Active Players: Distribution by Number of Antibody Drug Conjugates
Figure 5.1 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Approved / Marketed Targets
Figure 5.2 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Phase III Targets
Figure 5.3 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Phase II Targets
Figure 5.4 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Phase I Targets
Figure 5.4 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Pre-Clinical Stage Targets
Figure 5.5 Antibody Drug Conjugates: Six-Dimensional Spider Web Analysis
Figure 6.1 ADC Therapeutics: Annual Revenues, 2021-2022 (USD Million)
Figure 6.2 Astellas Pharma: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Figure 6.3 AstraZeneca: Annual Revenues, 2018-2022 (USD Billion)
Figure 6.4 Byondis: Annual Revenues, 2019-2022 (EUR Million)
Figure 6.5 Daiichi Sankyo: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Figure 6.6 Roche (Parent Company of Genentech): Annual Revenues, 2018-2022 (CHF Billion)
Figure 6.7 Gilead Sciences: Annual Revenues, 2018-2022 (USD Billion)
Figure 6.8 ImmunoGen: Annual Revenues, 2018-2022 (USD Million)
Figure 6.9 Pfizer: Annual Revenues, 2018-2022 (USD Billion)
Figure 6.10 RemeGen: Annual Revenues, 2021-9M 2022 (CNY Million)
Figure 6.11 Seagen: Annual Revenues, 2018-2022 (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2023
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2022
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.10 Clinical Trial Analysis: Distribution by Target Population
Figure 7.11 Clinical Trial Analysis: Distribution by Study Design
Figure 7.12 Most Active Industry Players: Distribution by Number of Trials
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 7.14 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 8.1 Antibody Drug Conjugates KOL Analysis: Distribution by Type of KOLs
Figure 8.2 Antibody Drug Conjugates KOL Analysis: Distribution by Qualification
Figure 8.3 Antibody Drug Conjugates KOL Analysis: Distribution by Affiliated Organization
Figure 8.4 Antibody Drug Conjugates KOL Analysis: Distribution by Type of Organization
Figure 8.5 Antibody Drug Conjugates: Geographical Distribution of KOLs
Figure 8.6 Most Prominent Principal Investigators: Analysis by KOL Activeness, Expertise and Strength
Figure 8.7 Most Prominent Study Directors and Study Chairs: Analysis by KOL Activeness, Expertise and Strength
Figure 8.8 Antibody Drug Conjugates Most Prominent KOLs: Distribution by RA Score
Figure 8.9 Antibody Drug Conjugates Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 8.10 Antibody Drug Conjugates Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.1 Antibody Drug Conjugates Clinical Studies: Distribution by Trial Registration Year and Type of Therapy
Figure 9.2 Antibody Drug Conjugate-based Combination Therapies: Distribution by Phase of Development
Figure 9.3 Antibody Drug Conjugate-based Combination Therapies: Distribution by Trial Status
Figure 9.4 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication
Figure 9.5 Most Popular Antibody Drug Conjugates Used in Combination Therapies: Distribution by Number of Trials
Figure 9.6 Most Popular Drug Classes Used in Antibody Drug Conjugate-based Combination Therapies: Distribution by Number of Trials
Figure 9.7 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication and Drug Class
Figure 9.8 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Blood Cancer
Figure 9.9 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Breast Cancer
Figure 9.10 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Renal Cancer
Figure 9.11 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Lung Cancer
Figure 9.12 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Ovarian Cancer
Figure 9.13 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Gastric Cancer
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2023
Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Most Active Players: Distribution by Number for Partnerships
Figure 10.7 Partnerships and Collaborations: International and Local Agreements
Figure 10.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Funding and Investment Analysis: Cumulative Distribution of Instances, Pre-2016-2023
Figure 11.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre-2016-2023 (USD Million)
Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
Figure 11.6 Funding and Investment Analysis: Distribution of Instances by Type of Investor
Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Figure 11.10 Most Active Players: Distribution by Number of Funding Instances
Figure 11.11 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.12 Key Investors: Distribution by Number of Instances
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2023
Figure 12.3 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre 2018 -2022
Figure 12.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Figure 12.7 Patent Analysis: Distribution by CPC Symbols
Figure 12.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
Figure 12.9 Leading Industry Players: Distribution by Number of Patents
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 12.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 12.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Figure 12.13 Patent Analysis: Distribution by Patent Age
Figure 12.14 Antibody Drug Conjugates: Patent Valuation
Figure 13.1 Grants Analysis: Cumulative Distribution by Year of Grant, 2016- 2023
Figure 13.2 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2016- 2023
Figure 13.3 Grants Analysis: Distribution by Funding Institute Center
Figure 13.4 Grants Analysis: Distribution by Support Period
Figure 13.5 Grants Analysis: Distribution by Type of Grant Application
Figure 13.6 Grants Analysis: Distribution by Purpose of Grant Award
Figure 13.7 Grants Analysis: Distribution by Activity Code
Figure 13.8 Grants Analysis: Distribution by Study Section Involved
Figure 13.9 Popular NIH Departments: Distribution by Number of Grants
Figure 13.10 Prominent Program Officers: Distribution by Number of Grants
Figure 13.11 Popular Recipient Organizations: Distribution by Number of Grants
Figure 13.12 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 13.13 Grants Analysis: Distribution by Region of Recipient Organization
Figure 14.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 14.2 Successful Drug Launch Strategy: Product Differentiation
Figure 14.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 14.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Developing Antibody Drug Conjugates
Figure 14.5 Antibody Drug Conjugates Approval in Multiple Geographies: Historical Timeline
Figure 14.6 Approved Antibody Drug Conjugates: Snapshot of Promotional Activities on Product Website
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Product Website Analysis: Adcetris, Messages for Healthcare Professionals
Figure 15.4 Product Website Analysis: Adcetris, Messages for Patients
Figure 15.5 Product Website Analysis: Adcetris, Patient Support Program
Figure 15.6 Product Website Analysis: Besponsa, Messages for Healthcare Professionals
Figure 15.7 Product Website Analysis: Besponsa, Messages for Patients
Figure 15.8 Product Website Analysis: Besponsa, Patient Support Program
Figure 15.9 Product Website Analysis: Enhertu, Messages for Healthcare Professionals
Figure 15.10 Product Website Analysis: Enhertu, Messages for Patients
Figure 15.11 Product Website Analysis: Enhertu, Patient Support Program
Figure 15.12 Product Website Analysis: Kadcyla, Messages for Healthcare Professionals
Figure 15.13 Product Website Analysis: Kadcyla, Messages for Patients
Figure 15.14 Product Website Analysis: Kadacyla, Patient Support Program
Figure 15.15 Product Website Analysis: Mylotarg, Messages for Healthcare Professionals
Figure 15.16 Product Website Analysis: Mylotarg, Messages for Patients
Figure 15.17 Product Website Analysis: Mylotarg, Patient Support Program
Figure 15.18 Product Website Analysis: Pfizer Oncology Together Program
Figure 15.19 Product Website Analysis: Polivy, Messages for Healthcare Professionals
Figure 15.20 Product Website Analysis: Polivy, Messages for Patients
Figure 15.21 Product Website Analysis: Polivy, Patient Support Program
Figure 15.22 Product Website Analysis: Trodelvy, Messages for Healthcare Professionals
Figure 15.23 Product Website Analysis: Messages for Patients
Figure 15.24 Product Website Analysis: Trodelvy, Patient Support Program
Figure 16.1 Adcetris (Seagen / Takeda Oncology): Approval Timeline
Figure 16.2 Adcetris (Seagen / Takeda Oncology): Success Protocol Analysis
Figure 16.3 Besponsa (UCB / Pfizer): Approval Timeline
Figure 16.4 Besponsa (UCB / Pfizer): Success Protocol Analysis
Figure 16.5 Elahere (ImmunoGen): Approval Timeline
Figure 16.6 Elahere (ImmunoGen): Success Protocol Analysis
Figure 16.7 Enhertu (Daiichi Sankyo / AstraZeneca): Approval Timeline
Figure 16.8 Enhertu (Daiichi Sankyo / AstraZeneca): Success Protocol Analysis
Figure 16.9 Kadcyla (Genentech / ImmunoGen): Approval Timeline
Figure 16.10 Kadcyla (Genentech / ImmunoGen): Success Protocol Analysis
Figure 16.11 Padcev (Seagen / Astellas Pharma): Approval Timeline
Figure 16.12 Padcev (Seagen / Astellas Pharma): Success Protocol Analysis
Figure 16.13 Polivy (Genentech): Approval Timeline
Figure 16.14 Polivy (Genentech): Success Protocol Analysis
Figure 16.15 Tivdak (Seagen / Genmab): Approval Timeline
Figure 16.16 Tivdak (Seagen / Genmab): Success Protocol Analysis
Figure 16.17 Trodelvy (Gilead Sciences): Approval Timeline
Figure 16.18 Trodelvy (Gilead Sciences): Success Protocol Analysis
Figure 16.19 Zynlonta (ADC Therapeutics): Approval Timeline
Figure 16.20 Zynlonta (ADC Therapeutics): Success Protocol Analysis
Figure 16.21 Success Protocol Analysis: Leading Parameters
Figure 18.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 18.2 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
Figure 19.1 Antibody Drug Conjugates: Key Manufacturing Steps
Figure 19.2 Antibody Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing
Figure 19.3 Antibody Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing (With Licensing Fees)
Figure 19.4 Antibody Drug Conjugates: Pricing Model Based on Patient Segment
Figure 20.1 Antibody Drug Conjugates: Manufacturing Steps
Figure 20.2 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 20.3 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 21.1 Advantages of Companion Diagnostics
Figure 21.2 Failure Rate: Distribution by Type of Drug Class
Figure 21.3 Companion Diagnostics: Primary Developmental Challenges
Figure 21.4 Companion Diagnostics for Antibody Therapeutics: Distribution by Target Antigen
Figure 21.5 Companion Diagnostics for Antibody Therapeutics: Distribution by Type of Cancer
Figure 21.6 Companion Diagnostics for Antibody Therapeutics: Distribution by Key Players
Figure 22.1 Antibody Drug Conjugates: SWOT Analysis
Figure 22.2 Antibody Drug Conjugates SWOT Analysis: Strengths
Figure 22.3 Antibody Drug Conjugates SWOT Analysis: Weaknesses
Figure 22.4 Antibody Drug Conjugates SWOT Analysis: Opportunities
Figure 22.5 Antibody Drug Conjugates SWOT Analysis: Threats
Figure 23.1 Global Antibody Drug Conjugates Market, 2023-2035 (USD Billion)
Figure 23.2 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)
Figure 23.3 Antibody Drug Conjugates Market for Breast Cancer, 2023-2035 (USD Billion)
Figure 23.4 Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035 (USD Billion)
Figure 23.5 Antibody Drug Conjugates Market for Lung Cancer, 2023-2035 (USD Billion)
Figure 23.6 Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035 (USD Billion)
Figure 23.7 Antibody Drug Conjugates Market for Renal Cancer, 2023-2035 (USD Billion)
Figure 23.8 Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035 (USD Billion)
Figure 23.9 Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035 (USD Billion)
Figure 23.10 Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035 (USD Billion)
Figure 23.11 Antibody Drug Conjugates Market for Other Target Disease Indications, 2023-2035 (USD Billion)
Figure 23.12 Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
Figure 23.13 Antibody Drug Conjugates Market for Solid Tumors, 2023-2035 (USD Billion)
Figure 23.14 Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035 (USD Billion)
Figure 23.15 Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035 (USD Billion)
Figure 23.16 Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035 (USD Billion)
Figure 23.17 Antibody Drug Conjugates Market for Tetrapeptide-based Linker, 2023-2035 (USD Billion)
Figure 23.18 Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035 (USD Billion)
Figure 23.19 Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035 (USD Billion)
Figure 23.20 Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035 (USD Billion)
Figure 23.21 Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035 (USD Billion)
Figure 23.22 Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035 (USD Billion)
Figure 23.23 Antibody Drug Conjugates Market for Other Linkers, 2023-2035 (USD Billion)
Figure 23.24 Antibody Drug Conjugates Market: Distribution by Payload, 2023 and 2035 (USD Billion)
Figure 23.25 Antibody Drug Conjugates Market for Monomethyl auristatin F (MMAF) Payload, 2023-2035 (USD Billion)
Figure 23.26 Antibody Drug Conjugates Market for DM1 Payload, 2023-2035 (USD Billion)
Figure 23.27 Antibody Drug Conjugates Market for SN-38 / Irinotecan Payload, 2023-2035 (USD Billion)
Figure 23.28 Antibody Drug Conjugates Market for Monomethyl auristatin E (MMAE) Payload, 2023-2035
Figure 23.29 Antibody Drug Conjugates Market for Duocarmycin Payload, 2023-2035 (USD Billion)
Figure 23.30 Antibody Drug Conjugates Market for SG3199 Payload, 2023-2035 (USD Billion)
Figure 23.31 Antibody Drug Conjugates Market for Ozogamicin Payload, 2023-2035 (USD Billion)
Figure 23.32 Antibody Drug Conjugates Market for DM4 Payload, 2023-2035 (USD Billion)
Figure 23.33 Antibody Drug Conjugates Market for Other Payloads, 2023-2035 (USD Billion)
Figure 23.34 Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035 (USD Billion)
Figure 23.35 Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035 (USD Billion)
Figure 23.36 Antibody Drug Conjugates Market for CD79b, 2023-2035 (USD Billion)
Figure 23.37 Antibody Drug Conjugates Market for TROP-2, 2023-2035 (USD Billion)
Figure 23.38 Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035 (USD Billion)
Figure 23.39 Antibody Drug Conjugates Market for CD19, 2023-2035 (USD Billion)
Figure 23.40 Antibody Drug Conjugates Market for Nectin 4, 2023-2035 (USD Billion)
Figure 23.41 Antibody Drug Conjugates Market for Tissue Factor, 2023-2035 (USD Billion)
Figure 23.42 Antibody Drug Conjugates Market for CD22, 2023-2035 (USD Billion)
Figure 23.43 Antibody Drug Conjugates Market for CD30, 2023-2035 (USD Billion)
Figure 23.44 Antibody Drug Conjugates Market for CEACAM5, 2023-2035 (USD Billion)
Figure 23.45 Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035 (USD Billion)
Figure 23.46 Antibody Drug Conjugates Market: Distribution by Key Geographical Regions, 2021 and 2030 (USD Billion)
Figure 23.47 Antibody Drug Conjugates Market in North America, 2023-2035 (USD Billion)
Figure 23.48 Antibody Drug Conjugates Market in US, 2023-2035 (USD Billion)
Figure 23.49 Antibody Drug Conjugates Market in Canada, 2023-2035 (USD Billion)
Figure 23.50 Antibody Drug Conjugates Market in Europe, 2023-2035 (USD Billion)
Figure 23.51 Antibody Drug Conjugates Market in Germany, 2023-2035 (USD Billion)
Figure 23.52 Antibody Drug Conjugates Market in UK, 2023-2035 (USD Billion)
Figure 23.53 Antibody Drug Conjugates Market in France, 2023-2035 (USD Billion)
Figure 23.54 Antibody Drug Conjugates Market in Italy, 2023-2035 (USD Billion)
Figure 23.55 Antibody Drug Conjugates Market in Spain, 2023-2035 (USD Billion)
Figure 23.56 Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 23.57 Antibody Drug Conjugates Market in China, 2023-2035 (USD Billion)
Figure 23.58 Antibody Drug Conjugates Market in Australia, 2023-2035 (USD Billion)
Figure 23.59 Antibody Drug Conjugates Market in Japan, 2023-2035 (USD Billion)
Figure 23.60 Adcetris: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.61 Aidixi: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.62 Besponsa: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.63 Blenrep: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.64 Elahere: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.65 Enhertu: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.66 Kadcyla: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.67 Padcev: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.68 Polivy: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.69 Tivdak: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.70 Trodelvy: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.71 Zynlonta: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.72 Datopotamab Deruxtecan: Sales Forecast, 2028-2035 (USD Billion)
Figure 23.73 Patritumab Deruxtecan: Sales Forecast, 2028-2035 (USD Billion)
Figure 23.74 SHR-A1811: Sales Forecast, 2026-2035 (USD Billion)
Figure 23.75 SKB264: Sales Forecast, 2026-2035 (USD Billion)
Figure 23.76 TAA013: Sales Forecast, 2024-2035 (USD Billion)
Figure 23.77 Telisotuzumab Vedotin: Sales Forecast, 2027-2035 (USD Billion)
Figure 23.78 Trastuzumab Duocarmazine: Sales Forecast, 2023-2035 (USD Billion)
Figure 23.79 Tusamitamab Ravtansine: Sales Forecast, 2026-2035 (USD Billion)
Figure 23.80 Upifitamab Rilsodotin: Sales Forecast, 2026-2035 (USD Billion)
Figure 25.1 Concluding Remarks: Market Overview
Figure 25.2 Concluding Remarks: Clinical Trials Landscape
Figure 25.3 Concluding Remarks: Partnerships and Collaborations
Figure 25.4 Concluding Remarks: Funding and Investment Analysis
Figure 25.5 Concluding Remarks: Patent Analysis
Figure 25.6 Concluding Remarks: Academic Grants Analysis
Figure 25.7 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1 List of Approved Monoclonal Antibody Therapies
Table 3.2 Characteristics of Small Molecules and Monoclonal Antibodies and Antibody Drug Conjugates
Table 3.3 Commonly Used Cytotoxins for Antibody Drug Conjugates
Table 3.4 Characteristics of First, Second and Third Generation Antibody Drug Conjugates
Table 4.1 Antibody Drug Conjugates: Information on Drug Candidates, Developer(s), Status of Development, Target Disease Indication(s), and Therapeutic Area(s)
Table 4.2 Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosing Frequency, Type of Therapy, Target Antigen and Antibody Isotype
Table 4.3 Antibody Drug Conjugates: Information on Drug Candidates, Payload / Cytotoxin / Warhead, Type of Payload, Linker and Type of Linker (Cleavable and Non-Cleavable)
Table 4.4 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size, and Location of Headquarters
Table 5.1 Target Competitiveness Analysis: Information on Novel Pre-Clinical Stage Targets, Drug Candidates, Developer(s), Target Disease Indication(s) and Therapeutics Area(s)
Table 6.1 List of Companies Profiled
Table 6.2 ADC Therapeutics: Company Overview
Table 6.3 ADC Therapeutics: Antibody Drug Conjugate Pipeline
Table 6.4 Drug Profile: Zynlonta
Table 6.5 ADC Therapeutics: Recent Developments and Future Outlook
Table 6.6 Astellas Pharma: Company Overview
Table 6.7 Astellas Pharma: Antibody Drug Conjugate Pipeline
Table 6.8 Drug Profile: Padcev
Table 6.9 Astellas Pharma: Recent Developments and Future Outlook
Table 6.10 AstraZeneca: Company Overview
Table 6.11 AstraZeneca: Antibody Drug Conjugate Pipeline
Table 6.12 Drug Profile: Enhertu
Table 6.13 AstraZeneca: Recent Developments and Future Outlook
Table 6.14 Byondis: Company Overview
Table 6.15 Byondis: Antibody Drug Conjugate Pipeline
Table 6.16 Drug Profile: Trastuzumab Duocarmazine
Table 6.17 Byondis: Recent Developments and Future Outlook
Table 6.18 Daiichi Sankyo: Company Overview
Table 6.19 Daiichi Sankyo: Antibody Drug Conjugate Pipeline
Table 6.20 Drug Profile: Enhertu
Table 6.21 Daiichi Sankyo: Recent Development and Future Outlook
Table 6.22 Genentech: Company Overview
Table 6.23 Genentech: Antibody Drug Conjugate Pipeline
Table 6.24 Drug Profile: Kadcyla
Table 6.25 Drug Profile: Polivy
Table 6.26 Roche / Genentech: Recent Developments and Future Outlook
Table 6.27 Gilead Sciences: Company Overview
Table 6.28 Gilead Sciences: Antibody Drug Conjugate Pipeline
Table 6.29 Drug Profile: Trodelvy
Table 6.30 Gilead Sciences: Recent Developments and Future Outlook
Table 6.31 ImmunoGen: Company Overview
Table 6.32 ImmunoGen: Antibody Drug Conjugate Pipeline
Table 6.33 Drug Profile: Elahere
Table 6.34 ImmunoGen: Recent Developments and Future Outlook
Table 6.35 Pfizer: Company Overview
Table 6.36 Pfizer: Antibody Drug Conjugate Pipeline
Table 6.37 Drug Profile: Mylotarg
Table 6.38 Drug Profile: Besponsa
Table 6.39 Pfizer: Recent Developments and Future Outlook
Table 6.40 RemeGen: Company Overview
Table 6.41 RemeGen: Antibody Drug Conjugate Pipeline
Table 6.42 Drug Profile: Disitamab vedotin
Table 6.43 RemeGen: Recent Developments and Future Outlook
Table 6.44 Seagen: Company Overview
Table 6.45 Seagen: Antibody Drug Conjugate Pipeline
Table 6.46 Drug Profile: Adcetris
Table 6.47 Drug Profile: Padcev
Table 6.48 Drug Profile: Tivdak
Table 6.49 Seagen: Recent Developments and Future Outlook
Table 8.1 Antibody Drug Conjugates: List of Principal Investigators
Table 10.1 Antibody Drug Conjugates: List of Partnerships and Collaborations, 2014-2023
Table 11.1 Antibody Drug Conjugates: List of Funding and Investments, 2014-2023
Table 11.2 Funding and Investment Analysis: Summary of Investments
Table 12.1 Patent Analysis: Top CPC Sections
Table 12.2 Patent Analysis: Top CPC Symbols
Table 12.3 Patent Analysis: Top CPC Codes
Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 12.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 14.1 List of Conferences Related to Approved Antibody Drug Conjugates
Table 14.2 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 15.1 Promotional / Marketing Strategy: Informative Downloads
Table 15.2 Adcetris: Drug Overview
Table 15.3 Besponsa: Drug Overview
Table 15.4 Enhertu: Drug Overview
Table 15.5 Kadcyla: Drug Overview
Table 15.6 Mylotarg: Drug Overview
Table 15.7 Polivy: Drug Overview
Table 15.8 Trodelvy: Drug Overview
Table 16.1 List of Top Approved Antibody Drug Conjugates
Table 16.2 Adcetris (Seagen / Takeda Oncology): Success Protocol Analysis Parameters
Table 16.3 Besponsa (UCB / Pfizer): Success Protocol Analysis Parameters
Table 16.4 Elahere (ImmunoGen): Success Protocol Analysis Parameters
Table 16.5 Enhertu (Seagen / Takeda Oncology): Success Protocol Analysis Parameters
Table 16.6 Kadcyla (Genentech / ImmunoGen): Success Protocol Analysis Parameters
Table 16.7 Padcev (Seagen / Astellas Pharma): Success Protocol Analysis Parameters
Table 16.8 Polivy (Genentech): Success Protocol Analysis Parameters
Table 16.9 Tivdak (Seagen / Genmab): Success Protocol Analysis Parameters
Table 16.10 Trodelvy (Gilead Sciences): Success Protocol Analysis Parameters
Table 16.11 Zynlonta (ADC Therapeutics): Success Protocol Analysis Parameters
Table 17.1 Antibody Drug Conjugate Conjugation Technologies: Information on Generation of Technology, Type of Specificity, Type of Conjugation and Drug Antibody Ratio
Table 17.2 Antibody Drug Conjugate Linker and Linker-Payload Technologies: Information on Manufacturer, Linker Name and Type of Linker
Table 18.1 Antibody Drug Conjugates Non-Clinical Studies: Safety Packages Required
Table 18.2 Kadcyla: GLP Toxicology Study Results
Table 18.3 Antibody Drug Conjugates: Dose Limiting Toxicities in Clinical Studies
Table 18.4 Antibody Drug Conjugates: Relationship Between Dose-Limiting Toxicities and Antibody Drug Conjugate Warhead
Table 19.1 Antibody Drug Conjugates Components: Information on the Cost of Different Types of Linkers
Table 19.2 Antibody Drug Conjugates Component: Information on Cost by Type of Cytotoxin
Table 19.3 Price of Marketed Antibody Drug Conjugates
Table 19.4 Price of Marketed Targeted Drugs
Table 20.1 Antibody Drug Conjugates Contract Manufacturing Service Providers: List of Companies
Table 20.2 Antibody Drug Conjugates Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Payloads Manufacturing Service Providers
Table 20.3 Antibody Drug Conjugates Contract Manufacturing Service Providers: Information on Scale of Operation
Table 20.4 Antibody Drug Conjugate Contract Manufacturing Service Providers: Information on Location of Dedicated Manufacturing Facilities
Table 21.1 Companion Diagnostics: List of Available / Under Development Tests for Antibody Drug Conjugates
Table 21.2 Companion Diagnostics: Partnerships and Collaborations, 2017-2021
Table 21.3 Companion Diagnostics for Antibody Therapeutics: List of Available / Under Development Tests
Table 23.1 Antibody Drug Conjugates: List of Forecasted Therapies
Table 23.2 Adcetris (Seagen / Takeda Oncology): Net Present Value (USD Billion)
Table 23.3 Adcetris (Seagen / Takeda Oncology): Value Creation Analysis (USD Billion)
Table 23.4 Aidixi (RemeGen): Net Present Value (USD Billion)
Table 23.5 Aidixi (RemeGen): Value Creation Analysis (USD Billion)
Table 23.6 Besponsa (Pfizer / UCB): Net Present Value (USD Billion)
Table 23.7 Besponsa (Pfizer / UCB): Value Creation Analysis (USD Billion)
Table 23.8 Blenrep (GSK): Net Present Value (USD Billion)
Table 23.9 Blenrep (GSK): Value Creation Analysis (USD Billion)
Table 23.10 Elahere (ImmunoGen): Net Present Value (USD Billion)
Table 23.11 Elahere (ImmunoGen): Value Creation Analysis (USD Billion)
Table 23.12 Enhertu (Daiichi Sankyo / AstraZeneca): Net Present Value (USD Billion)
Table 23.13 Enhertu (Daiichi Sankyo / AstraZeneca): Value Creation Analysis (USD Billion)
Table 23.14 Kadcyla (Genentech / ImmunoGen): Net Present Value (USD Billion)
Table 23.15 Kadcyla (Genentech / ImmunoGen): Value Creation Analysis (USD Billion)
Table 23.16 Padcev (Seagen / Astellas Pharma): Net Present Value (USD Billion)
Table 23.17 Padcev (Seagen / Astellas Pharma): Value Creation Analysis (USD Billion)
Table 23.18 Polivy (Genentech): Net Present Value (USD Billion)
Table 23.19 Polivy (Genentech): Value Creation Analysis (USD Billion)
Table 23.20 Tivdak (Seagen / Genmab): Net Present Value (USD Billion)
Table 23.21 Tivdak (Seagen / Genmab): Value Creation Analysis (USD Billion)
Table 23.22 Trodelvy (Gilead Sciences): Net Present Value (USD Billion)
Table 23.23 Trodelvy (Gilead Sciences): Value Creation Analysis (USD Billion)
Table 23.24 Zynlonta (ADC Therapeutics): Net Present Value (USD Billion)
Table 23.25 Zynlonta (ADC Therapeutics): Value Creation Analysis (USD Billion)
Table 23.26 Datopotamab Deruxtecan (Daiichi Sankyo): Net Present Value (USD Billion)
Table 23.27 Datopotamab Deruxtecan (Daiichi Sankyo): Value Creation Analysis (USD Billion)
Table 23.28 Patritumab Deruxtecan (Daiichi Sankyo): Net Present Value (USD Billion)
Table 23.29 Patritumab Deruxtecan (Daiichi Sankyo): Value Creation Analysis (USD Billion)
Table 23.30 SHR-A1811 (Luzsana Biotechnology): Net Present Value (USD Billion)
Table 23.31 SHR-A1811 (Luzsana Biotechnology): Value Creation Analysis (USD Billion)
Table 23.32 SKB264 (Klus Pharma): Net Present Value (USD Billion)
Table 23.33 SKB264 (Klus Pharma): Value Creation Analysis (USD Billion)
Table 23.34 TAA013 (Tot Biopharm): Net Present Value (USD Billion)
Table 23.35 TAA013 (Tot Biopharm): Value Creation Analysis (USD Billion)
Table 23.36 Telisotuzumab Vedotin (Abbvie): Net Present Value (USD Billion)
Table 23.37 Telisotuzumab Vedotin (Abbvie): Value Creation Analysis (USD Billion)
Table 23.38 Trastuzumab Duocarmazine (Byondis): Net Present Value (USD Billion)
Table 23.39 Trastuzumab Duocarmazine (Byondis): Value Creation Analysis (USD Billion)
Table 23.40 Tusamitamab Ravtansine (Sanofi / ImmunoGen): Net Present Value (USD Billion)
Table 23.41 Tusamitamab Ravtansine (Sanofi / ImmunoGen): Value Creation Analysis (USD Billion)
Table 23.42 Upifitamab Rilsodotin (Mersana Therapeutics): Net Present Value (USD Billion)
Table 23.43 Upifitamab Rilsodoti (Mersana Therapeutics): Value Creation Analysis (USD Billion)
Table 24.1 Angiex: Key Highlights
Table 24.2 Syndivia: Key Highlights
Table 24.3 BSP Pharmaceuticals: Key Highlights
Table 24.4 PolyTherics: Key Highlights
Table 24.5 CureMeta: Key Highlights
Table 24.6 CytomX: Key Highlights
Table 24.7 NBE-Therapeutics: Key Highlights
Table 24.8 Cerbios-Pharma: Key Highlights
Table 24.9 Eisai: Key Highlights
Table 24.10 AbTis: Key Highlights
Table 24.11 AmbrX: Key Highlights
Table 24.12 Synaffix: Key Highlights
Table 24.13 Pierre Fabre: Key Highlights
Table 24.14 Catalent Pharma Solutions: Key Highlights
Table 24.15 Lonza: Key Highlights
Table 24.16 Piramal Healthcare: Key Highlights
Table 24.17 Ajinomoto Bio-Pharma Services: Key Highlights
Table 24.18 Cardiff University: Key Highlights
Table 26.1 Antibody Drug Conjugates: Distribution by Status of Development
Table 26.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 26.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
Table 26.4 Antibody Drug Conjugates: Distribution by Line of Treatment
Table 26.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 26.6 Antibody Drug Conjugates: Distribution by Type of Therapy
Table 26.7 Antibody Drug Conjugates: Distribution by Target Antigen
Table 26.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 26.9 Antibody Drug Conjugates: Distribution by Type of Payload / Cytotoxin / Warhead
Table 26.10 Antibody Drug Conjugates: Distribution by Type of Payload
Table 26.11 Antibody Drug Conjugates: Distribution by Linker
Table 26.12 Antibody Drug Conjugates: Distribution by Type of Linker
Table 26.13 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 26.14 Antibody Drug Conjugates Developers: Distribution by Company Size
Table 26.15 Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Table 26.16 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
Table 26.17 Most Active Players: Distribution by Number of Antibody Drug Conjugates
Table 26.18 ADC Therapeutics: Annual Revenues, 2021-2022 (USD Million)
Table 26.19 Astellas Pharma: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Table 26.20 AstraZeneca: Annual Revenues, 2018-2022 (USD Billion)
Table 26.21 Byondis: Annual Revenues, 2019-2022 (EUR Million)
Table 26.22 Daiichi Sankyo: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Table 26.23 Roche (Parent Company of Genentech): Annual Revenues, 2018-2022 (CHF Billion)
Table 26.24 Gilead Sciences: Annual Revenues, 2018-2022 (USD Billion)
Table 26.25 ImmunoGen: Annual Revenues, 2018-2022 (USD Million)
Table 26.26 Pfizer: Annual Revenues, 2018-2022 (USD Billion)
Table 26.27 RemGen: Annual Revenues, 2021-9M 2022 (CNY Million)
Table 26.28 Seagen: Annual Revenues, 2018-2022 (USD Million)
Table 26.29 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2023
Table 26.30 Clinical Trial Analysis: Distribution by Trial Status
Table 26.31 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 26.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2022
Table 26.33 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
Table 26.34 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.35 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 26.36 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.37 Clinical Trial Analysis: Distribution by Target Population
Table 26.38 Clinical Trial Analysis: Distribution by Study Design
Table 26.39 Most Active Industry Players: Distribution by Number of Trials
Table 26.40 Most Active Non-Industry Players: Distribution by Number of Trials
Table 26.41 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 26.42 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 26.43 Antibody Drug Conjugates KOL Analysis: Distribution by Type of KOLs
Table 26.44 Antibody Drug Conjugates KOL Analysis: Distribution by Qualification(s)
Table 26.45 Antibody Drug Conjugates KOL Analysis: Distribution by Affiliated Organization
Table 26.46 Antibody Drug Conjugates KOL Analysis: Distribution by Type of Organization
Table 26.47 Antibody Drug Conjugates: Geographical Distribution of KOLs
Table 26.48 Antibody Drug Conjugates Most Prominent KOLs: Distribution by RA Score
Table 26.49 Antibody Drug Conjugates Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 26.50 Antibody Drug Conjugates Clinical Studies: Distribution by Trial Registration Year and Type of Therapy
Table 26.51 Antibody Drug Conjugate-based Combination Therapies: Distribution by Phase of Development
Table 26.52 Antibody Drug Conjugate-based Combination Therapies: Distribution by Trial Status
Table 26.53 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication
Table 26.54 Most Popular Antibody Drug Conjugates Used in Combination Therapies: Distribution by Number of Trials
Table 26.55 Most Popular Drug Classes Used in Antibody Drug Conjugate-based Combination Therapies: Distribution by Number of Trials
Table 26.56 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2023
Table 26.57 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.58 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2023
Table 26.59 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 26.60 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.61 Most Active Players: Distribution by Number for Partnerships
Table 26.62 Partnerships and Collaborations: International and Local Agreements
Table 26.63 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 26.64 Funding and Investment Analysis: Cumulative Distribution of Instances, Pre-2016-2023
Table 26.65 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre-2016-2023 (USD Million)
Table 26.66 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 26.67 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 26.68 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
Table 26.69 Funding and Investment Analysis: Distribution of Instances by Type of Investor
Table 26.70 Funding and Investment Analysis: Distribution of Funding Instances by Region
Table 26.71 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Table 26.72 Most Active Players: Distribution by Number of Funding Instances
Table 26.73 Most Active Players: Distribution by Amount Invested (USD Million)
Table 26.74 Key Investors: Distribution by Number of Instances
Table 26.75 Patent Analysis: Distribution by Type of Patent
Table 26.76 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2023
Table 26.77 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre 2018 -2022
Table 26.78 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Table 26.79 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Table 26.80 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Table 26.81 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
Table 26.82 Leading Industry Players: Distribution by Number of Patents
Table 26.83 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.84 Leading Individual Assignees: Distribution by Number of Patents
Table 26.85 Patent Analysis: Distribution by Patent Age
Table 26.86 Grants Analysis: Cumulative Distribution by Year of Grant, 2016- 2023
Table 26.87 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2016- 2023
Table 26.88 Grants Analysis: Distribution by Funding Institute Center
Table 26.89 Grants Analysis: Distribution by Support Period
Table 26.90 Grants Analysis: Distribution by Type of Grant Applications
Table 26.91 Grants Analysis: Distribution by Purpose of Grant Award
Table 26.92 Grants Analysis: Distribution by Activity Code
Table 26.93 Grants Analysis: Distribution by Study Section Involved
Table 26.94 Popular NIH Departments: Distribution by Number of Grants
Table 26.95 Prominent Program Officers: Distribution by Number of Grants
Table 26.96 Popular Recipient Organizations: Distribution by Number of Grants
Table 26.97 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 26.98 Grants Analysis: Distribution by Region of Recipient Organization
Table 26.99 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Scale of Operation
Table 26.100 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Table 26.101 Companion Diagnostics for Antibody Therapeutics: Distribution by Target Antigen
Table 26.102 Companion Diagnostics for Antibody Therapeutics: Distribution by Type of Cancer
Table 26.103 Companion Diagnostics for Antibody Therapeutics: Distribution by Key Players
Table 26.104 Global Antibody Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.105 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)
Table 26.106 Antibody Drug Conjugates Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.107 Antibody Drug Conjugates Market for B-cell Lymphoma, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.108 Antibody Drug Conjugates Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.109 Antibody Drug Conjugates Market for Multiplr Myeloma, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.110 Antibody Drug Conjugates Market for Renal Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.111 Antibody Drug Conjugates Market for Gastric Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.112 Antibody Drug Conjugates Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.113 Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.114 Antibody Drug Conjugates Market for Other Target Disease Indication, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.115 Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
Table 26.116 Antibody Drug Conjugates Market for Solid Tumors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.117 Antibody Drug Conjugates Market for Hematological Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.118 Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Linker (USD Billion)
Table 26.119 Antibody Drug Conjugates Market for Valine-Citrulline Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.120 Antibody Drug Conjugates Market for Tetrapeptide-based Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.121 Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.122 Antibody Drug Conjugates Market for Maleimide Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.123 Antibody Drug Conjugates Market for Maleimidocaproyl Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.124 Antibody Drug Conjugates Market for Valine-alanine Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.125 Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.126 Antibody Drug Conjugates Market for Other Linkers, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.127 Global Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Payload (USD Billion)
Table 26.128 Antibody Drug Conjugates Market for Monomethyl auristatin F (MMAF) Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.129 Antibody Drug Conjugates Market for DM1 Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.130 Antibody Drug Conjugates Market for SN-38 / Irinotecan Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.131 Antibody Drug Conjugates Market for Monomethyl auristatin E (MMAE) Payload, Conservative, Base and Optimistic Scenarios, 2023-2035
Table 26.132 Antibody Drug Conjugates Market for Duocarmycin Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.133 Antibody Drug Conjugates Market for SG3199 Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.134 Antibody Drug Conjugates Market for Ozogamicin Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.135 Antibody Drug Conjugates Market for DM4 Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.136 Antibody Drug Conjugates Market for Other Payloads, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.137 Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Target Antigen (USD Billion)
Table 26.138 Antibody Drug Conjugates Market for HER-2 (ERBB2), Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.139 Antibody Drug Conjugates Market for CD79b, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.140 Antibody Drug Conjugates Market for TROP-2, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.141 Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.142 Antibody Drug Conjugates Market for CD19, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.143 Antibody Drug Conjugates Market for Nectin 4, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.144 Antibody Drug Conjugates Market for Tissue Factor, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.145 Antibody Drug Conjugates Market for CD22, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.146 Antibody Drug Conjugates Market for CD30, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.147 Antibody Drug Conjugates Market for CEACAM5, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.148 Antibody Drug Conjugates Market for Other Target Antigens, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.149 Global Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Key Geographical Regions (USD Billion)
Table 26.150 Antibody Drug Conjugates Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.151 Antibody Drug Conjugates Market in US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.152 Antibody Drug Conjugates Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.153 Antibody Drug Conjugates Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.154 Antibody Drug Conjugates Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.155 Antibody Drug Conjugates Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.156 Antibody Drug Conjugates Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.157 Antibody Drug Conjugates Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.158 Antibody Drug Conjugates Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.159 Antibody Drug Conjugates Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.160 Antibody Drug Conjugates Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.161 Antibody Drug Conjugates Market in Australia,, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.162 Antibody Drug Conjugates Market in Japan,, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.163 Adcetris: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.164 Aidixi: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.165 Besponsa: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.166 Blenrep: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.167 Elahere: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.168 Enhertu: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.169 Kadcyla: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.170 Padcev: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.171 Polivy: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.172 Tivdak: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.173 Trodelvy: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.174 Zynlonta: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.175 Datopotamab Deruxtecan: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
Table 26.176 Patritumab Deruxtecan: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
Table 26.177 SHR-A1811: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
Table 26.178 SKB264: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
Table 26.179 TAA013: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Billion)
Table 26.180 Telisotuzumab Vedotin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2027-2035 (USD Billion)
Table 26.181 Trastuzumab Duocarmazine: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 26.182 Tusamitamab Ravtansine: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
Table 26.183 Upifitamab Rilsodotin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
The following companies and organizations have been mentioned in the report:
Source 1: https://pubmed.ncbi.nlm.nih.gov/30859213/
Source 2: https://axispharm.com/antibody-drug-conjugatesadcs-list-approved-by-fda2000-2022/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES